Gross Profit Summary of CEL-SCI Corporation

CEL-SCI Corporation's latest annual gross profit in 2023 was -3.95 Million USD , down -1.93% from previous year.
CEL-SCI Corporation's latest quarterly gross profit in 2024 Q2 was -988.76 Thousand USD , up 1.58% from previous quarter.
CEL-SCI Corporation reported a annual gross profit of -3.88 Million USD in annual gross profit 2022, down -678.23% from previous year.
CEL-SCI Corporation reported a annual gross profit of -499 Thousand USD in annual gross profit 2021, down -192.27% from previous year.
CEL-SCI Corporation reported a quarterly gross profit of -983.2 Thousand USD for 2024 Q3, up 0.56% from previous quarter.
CEL-SCI Corporation reported a quarterly gross profit of -1 Million USD for 2024 Q1, down -0.6% from previous quarter.

Annual Gross Profit Chart of CEL-SCI Corporation (2023 - 1989)

Historical Annual Gross Profit of CEL-SCI Corporation (2023 - 1989)

Year	Gross Profit	Gross Profit Growth
2023	-3.95 Million USD	-1.93%
2022	-3.88 Million USD	-678.23%
2021	-499 Thousand USD	-192.27%
2020	540.82 Thousand USD	20.16%
2019	450.09 Thousand USD	-3.34%
2018	465.64 Thousand USD	182.56%
2017	-563.98 Thousand USD	-310.75%
2016	267.61 Thousand USD	-58.07%
2015	638.18 Thousand USD	4354.02%
2014	-15 Thousand USD	-19.81%
2013	-12.52 Thousand USD	-105.13%
2012	244.24 Thousand USD	-74.46%
2011	956.15 Thousand USD	523.71%
2010	153.3 Thousand USD	91.4%
2009	80.09 Thousand USD	1481.3%
2008	5065.00 USD	-91.12%
2007	57.04 Thousand USD	-54.53%
2006	125.45 Thousand USD	-53.52%
2005	269.92 Thousand USD	-17.07%
2004	325.47 Thousand USD	2.25%
2003	318.3 Thousand USD	-17.31%
2002	384.93 Thousand USD	2.32%
2001	376.22 Thousand USD	-6.42%
2000	402.01 Thousand USD	0.5%
1999	400 Thousand USD	300.0%
1998	100 Thousand USD	-75.0%
1997	400 Thousand USD	33.33%
1996	300 Thousand USD	200.0%
1995	100 Thousand USD	0.0%
1994	100 Thousand USD	133.33%
1993	-300 Thousand USD	-200.0%
1992	-100 Thousand USD	0.0%
1991	- USD	-100.0%
1990	100 Thousand USD	0.0%
1989	100 Thousand USD	0.0%

Year	Gross Profit	Gross Profit Growth
2024 Q2	-988.76 Thousand USD	1.58%
2024 Q3	-983.2 Thousand USD	0.56%
2024 Q1	-1 Million USD	-0.6%
2023 Q2	-989.9 Thousand USD	0.37%
2023 Q4	-998.65 Thousand USD	-0.98%
2023 Q3	-988.94 Thousand USD	0.1%
2023 FY	-3.95 Million USD	-1.93%
2023 Q1	-993.62 Thousand USD	4.22%
2022 Q3	-978.78 Thousand USD	0.05%
2022 Q1	-887.93 Thousand USD	-52.72%
2022 Q2	-979.26 Thousand USD	-10.29%
2022 FY	-3.88 Million USD	-678.23%
2022 Q4	-1.03 Million USD	-5.99%
2021 Q1	-5414.76 USD	-5.52%
2021 Q2	-550.79 Thousand USD	-10072.1%
2021 Q3	-548.22 Thousand USD	0.47%
2021 FY	-499 Thousand USD	-192.27%
2021 Q4	-581.4 Thousand USD	-6.05%
2020 Q4	-5131.30 USD	99.46%
2020 FY	540.82 Thousand USD	20.16%
2020 Q3	-954.9 Thousand USD	-22855.41%
2020 Q2	-4159.82 USD	1.36%
2020 Q1	-4217.31 USD	-27.3%
2019 FY	450.09 Thousand USD	-3.34%
2019 Q1	-3345.30 USD	-10.73%
2019 Q2	-2681.78 USD	19.83%
2019 Q3	-2856.57 USD	-6.52%
2019 Q4	-3312.88 USD	-15.97%
2018 Q2	-2848.03 USD	-102.55%
2018 Q1	111.57 Thousand USD	4844.57%
2018 Q3	-2339.10 USD	17.87%
2018 FY	465.64 Thousand USD	182.56%
2018 Q4	-3021.15 USD	-29.16%
2017 Q2	-6561.44 USD	-85.82%
2017 FY	-563.98 Thousand USD	-310.75%
2017 Q4	-2351.53 USD	25.66%
2017 Q1	-3531.00 USD	14.66%
2017 Q3	-3163.01 USD	51.79%
2016 FY	267.61 Thousand USD	-58.07%
2016 Q1	-4671.93 USD	-100.72%
2016 Q4	-4137.65 USD	2.22%
2016 Q3	-4231.53 USD	-2.73%
2016 Q2	-4119.21 USD	11.83%
2015 Q4	651.98 Thousand USD	12313.13%
2015 FY	638.18 Thousand USD	4354.02%
2015 Q1	-4717.98 USD	-9.59%
2015 Q3	-5338.35 USD	-9.42%
2015 Q2	-4878.81 USD	-3.41%
2014 FY	-15 Thousand USD	-19.81%
2014 Q2	-4086.84 USD	-4.62%
2014 Q3	-4437.82 USD	-8.59%
2014 Q4	-4305.06 USD	2.99%
2014 Q1	-3906.40 USD	-13.01%
2013 Q2	15.41 USD	100.53%
2013 FY	-12.52 Thousand USD	-105.13%
2013 Q4	-3456.70 USD	5.45%
2013 Q3	-3655.81 USD	-23831.32%
2013 Q1	-2909.72 USD	-102.69%
2012 Q1	5024.00 USD	-97.08%
2012 Q4	108.04 Thousand USD	208.69%
2012 Q3	35 Thousand USD	-67.15%
2012 Q2	106.54 Thousand USD	2020.68%
2012 FY	244.24 Thousand USD	-74.46%
2011 Q1	662.81 Thousand USD	972.52%
2011 Q4	172.11 Thousand USD	122.37%
2011 Q2	43.81 Thousand USD	-93.39%
2011 FY	956.15 Thousand USD	523.71%
2011 Q3	77.4 Thousand USD	76.66%
2010 Q2	30.6 Thousand USD	2.0%
2010 Q1	30 Thousand USD	0.0%
2010 Q3	30.9 Thousand USD	0.98%
2010 Q4	61.8 Thousand USD	100.0%
2010 FY	153.3 Thousand USD	91.4%
2009 Q4	30 Thousand USD	-1.48%
2009 Q3	30.45 Thousand USD	55.02%
2009 Q2	19.64 Thousand USD	0.0%
2009 FY	80.09 Thousand USD	1481.3%
2009 Q1	- USD	0.0%
2008 FY	5065.00 USD	-91.12%
2008 Q4	- USD	-100.0%
2008 Q1	1530.00 USD	-69.88%
2008 Q2	- USD	-100.0%
2008 Q3	3535.00 USD	0.0%
2007 Q1	13.86 Thousand USD	-27.37%
2007 FY	57.04 Thousand USD	-54.53%
2007 Q4	5079.00 USD	-21.24%
2007 Q3	6449.00 USD	-73.91%
2007 Q2	24.72 Thousand USD	78.34%
2006 Q2	36.81 Thousand USD	23.35%
2006 Q1	29.84 Thousand USD	-35.85%
2006 FY	125.45 Thousand USD	-53.52%
2006 Q4	19.08 Thousand USD	-51.93%
2006 Q3	39.7 Thousand USD	7.86%
2005 Q3	38.1 Thousand USD	-65.29%
2005 Q2	109.78 Thousand USD	45.4%
2005 Q1	75.5 Thousand USD	5.61%
2005 FY	269.92 Thousand USD	-17.07%
2005 Q4	46.53 Thousand USD	22.12%
2004 Q4	71.49 Thousand USD	-12.31%
2004 Q3	81.53 Thousand USD	-17.82%
2004 Q2	99.21 Thousand USD	35.47%
2004 Q1	73.23 Thousand USD	-39.37%
2004 FY	325.47 Thousand USD	2.25%
2003 Q2	82.68 Thousand USD	56.15%
2003 Q1	52.95 Thousand USD	551.03%
2003 Q3	61.87 Thousand USD	-25.17%
2003 FY	318.3 Thousand USD	-17.31%
2003 Q4	120.78 Thousand USD	95.2%
2002 Q1	176.24 Thousand USD	200.73%
2002 Q4	8134.00 USD	-92.43%
2002 Q3	107.51 Thousand USD	15.54%
2002 Q2	93.05 Thousand USD	-47.2%
2002 FY	384.93 Thousand USD	2.32%
2001 Q4	-174.96 Thousand USD	-181.95%
2001 Q1	249.8 Thousand USD	-37.86%
2001 Q2	87.88 Thousand USD	-64.82%
2001 Q3	213.49 Thousand USD	142.91%
2001 FY	376.22 Thousand USD	-6.42%
2000 Q2	78.89 Thousand USD	-21.1%
2000 FY	402.01 Thousand USD	0.5%
2000 Q1	100 Thousand USD	-66.67%
2000 Q4	402.01 Thousand USD	40200900.0%
2000 Q3	1.00 USD	-100.0%
1999 Q2	100 Thousand USD	0.0%
1999 Q3	100 Thousand USD	0.0%
1999 Q4	300 Thousand USD	200.0%
1999 FY	400 Thousand USD	300.0%
1999 Q1	100 Thousand USD	0.0%
1998 FY	100 Thousand USD	-75.0%
1998 Q1	100 Thousand USD	-66.67%
1998 Q2	100 Thousand USD	0.0%
1998 Q3	100 Thousand USD	0.0%
1998 Q4	- USD	-100.0%
1997 Q4	300 Thousand USD	200.0%
1997 Q2	100 Thousand USD	0.0%
1997 Q3	100 Thousand USD	0.0%
1997 FY	400 Thousand USD	33.33%
1997 Q1	100 Thousand USD	0.0%
1996 Q3	100 Thousand USD	0.0%
1996 Q1	100 Thousand USD	0.0%
1996 FY	300 Thousand USD	200.0%
1996 Q4	100 Thousand USD	0.0%
1996 Q2	100 Thousand USD	0.0%
1995 Q3	100 Thousand USD	0.0%
1995 Q1	100 Thousand USD	0.0%
1995 Q2	100 Thousand USD	0.0%
1995 Q4	- USD	-100.0%
1995 FY	100 Thousand USD	0.0%
1994 Q2	300 Thousand USD	50.0%
1994 Q3	100 Thousand USD	-66.67%
1994 Q4	- USD	-100.0%
1994 FY	100 Thousand USD	133.33%
1994 Q1	200 Thousand USD	-50.0%
1993 Q1	200 Thousand USD	166.67%
1993 Q4	400 Thousand USD	100.0%
1993 Q2	-200 Thousand USD	-200.0%
1993 FY	-300 Thousand USD	-200.0%
1993 Q3	200 Thousand USD	200.0%
1992 Q4	-300 Thousand USD	-400.0%
1992 Q1	100 Thousand USD	0.0%
1992 Q2	100 Thousand USD	0.0%
1992 FY	-100 Thousand USD	0.0%
1992 Q3	100 Thousand USD	0.0%
1991 Q2	100 Thousand USD	0.0%
1991 Q3	100 Thousand USD	0.0%
1991 Q4	- USD	-100.0%
1991 Q1	100 Thousand USD	0.0%
1991 FY	- USD	-100.0%
1990 FY	100 Thousand USD	0.0%
1990 Q4	- USD	-100.0%
1990 Q3	100 Thousand USD	0.0%
1990 Q2	100 Thousand USD	0.0%
1990 Q1	100 Thousand USD	0.0%
1989 Q3	100 Thousand USD	0.0%
1989 Q4	- USD	-100.0%
1989 Q2	100 Thousand USD	0.0%
1989 Q1	100 Thousand USD	0.0%
1989 FY	100 Thousand USD	0.0%

Peer Gross Profit Comparison of CEL-SCI Corporation

Name	Gross Profit	Gross Profit Difference
AIM ImmunoTech Inc.	160 Thousand USD	2573.959%
Ampio Pharmaceuticals, Inc.	-250 Thousand USD	-1483.334%
Armata Pharmaceuticals, Inc.	-29.24 Million USD	86.463%
Actinium Pharmaceuticals, Inc.	-709 Thousand USD	-458.298%
Azitra, Inc.	260.45 Thousand USD	1619.8%
Can-Fite BioPharma Ltd.	743 Thousand USD	632.75%
Chromocell Therapeutics Corporation	-2.57 Million USD	-53.458%
Calidi Biotherapeutics, Inc.	-1.25 Million USD	-215.154%
iBio, Inc.	-1.02 Million USD	-286.179%
Lineage Cell Therapeutics, Inc.	8.27 Million USD	147.841%
MAIA Biotechnology, Inc.	- USD	Infinity%
Matinas BioPharma Holdings, Inc.	-13.39 Million USD	70.445%
Navidea Biopharmaceuticals, Inc.	-119.29 Thousand USD	-3218.106%
NovaBay Pharmaceuticals, Inc.	7.89 Million USD	150.137%
NanoViricides, Inc.	-759.01 Thousand USD	-421.51%
Oragenics, Inc.	-15.45 Million USD	74.385%
BiomX Inc.	-1.22 Million USD	-222.34%
BiomX Inc.	-1.22 Million USD	-222.34%
Protalix BioTherapeutics, Inc.	42.51 Million USD	109.311%
Palatin Technologies, Inc.	4.39 Million USD	190.117%
Scorpius Holdings, Inc.	-2.21 Million USD	-78.592%

Global Stocks Search

CEL-SCI Corporation (CVM)

Gross Profit Summary of CEL-SCI Corporation

Annual Gross Profit Chart of CEL-SCI Corporation (2023 - 1989)

Historical Annual Gross Profit of CEL-SCI Corporation (2023 - 1989)

Peer Gross Profit Comparison of CEL-SCI Corporation